Home › Kidney Stones › NCT07087977

HoYAG vs TFL in miniPCNL With ClearPetra

Holmium:YAG Laser With MOSES Technology vs Thulium Fiber Laser in Supine Mini-percutaneous Nephrolithotomy With Vacuum-assisted Renal Access Sheath: A Prospective, Randomized Clinical Trial

Who can join

Ages 18 and older · All sexes

Inclusion Criteria:

1. Males or females over 18 years of age
2. Patients with kidney stones, with stone burden larger than 15 mm.
3. Patients undergoing new percutaneous access with primary, supine, unilateral mini-PCNL.

   Exclusion Criteria:
4. Simultaneous use of more than 1 laser platform or other form of fragmentation (e.g., ultrasonic).
5. Patients undergoing simultaneous treatment of contralateral kidney stones during the same procedure.
6. Patients undergoing simultaneous treatment of ureteral stones during the same procedure.
7. Pregnant patients.
8. Presence of genitourinary anatomical abnormalities.
9. Uncorrected coagulopathy.
10. External urinary catheters.
11. Immunosuppressed patients.
12. Non-elective procedures.

About the study

Mini percutaneous nephrolithotripsy is the treatment of choice for kidney stones over 2cm. This procedure commonly uses laser energy for breaking the stones, and among possible laser platforms, Hoyag and thulium fiber laser are FDA approved. Recently, this procedure has also included the use of vacuum assisted renal access sheaths, which allows suction to be employed together with the breaking of stones. This study intends to compare outcomes when using either laser platforms with suction sheaths in participants undergoing mini percutaneous nephrolithotripsy for the treatment of kidney stones.

What is being tested

• HoYAG laser (device)
• TFL laser platform (device)

Sponsor: University of Kansas Medical Center · Participants: 150 · Started: Aug 22, 2025

Contact the study team

• Jane Ledesma · Phone: 913-588-8721

Official record on ClinicalTrials.gov — NCT07087977

Locations in the U.S.

Conditions

• Kidney Stones

From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.